Beam Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 14 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.8 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 114.04% +1.81pp
- Institutions
- 325 -14
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 31 sells
| Name | Role | Stake |
|---|---|---|
| FMR | -- | 12.11% |
| John Evans | Chief Executive Officer | 0.95% |
| Giuseppe Ciaramella | President | 0.17% |
| Christine Bellon | Chief Legal Officer | 0.11% |
| Robert Taylor Nelsen | Former Independent Director | 0.06% |
| Mark Fishman | Lead Independent Director | 0.02% |
| Bethany Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer | 0.01% |
| Sravan Emany | Chief Financial Officer | 0.01% |
| Amy Simon | Chief Medical Officer | 0.00% |
| John Michael Maraganore | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | John Evans | Chief Executive Officer | Derivative Exercise and Sale | -50,000 | $1.03–23.98 |
| 2026-10-15 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $23.98 |
| 2026-10-14 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $23.57 |
| 2026-09-30 | Bethany Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer | Automatic Disposition | -187 | $24.41 |
| 2026-09-23 | Giuseppe Ciaramella | President | Other Disposition | -123,407 | -- |
| 2026-07-26 | Amy Simon | Chief Medical Officer | Automatic Disposition | -16,667 | $25.74 |
| 2026-06-29 | John Evans | Chief Executive Officer | Derivative Exercise and Sale | -50,000 | $0.67–35.91 |
| 2026-06-29 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $34.31 |
| 2026-06-29 | Amy Simon | Chief Medical Officer | Automatic Disposition | -373 | $34.73 |
| 2026-06-28 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -25,000 | $35.49 |
| 2026-06-16 | Giuseppe Ciaramella | President | Derivative Exercise and Retained | +35,505 | $0.67–1.03 |
| 2026-06-02 | John Michael Maraganore | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 |
| 2026-06-02 | Mark Fishman | Lead Independent Director | Other Derivative Acquisition | +19,676 | $29.55 |
| 2026-06-02 | Graham Cooper | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 |
| 2026-06-02 | Kathleen Walsh | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 |
| 2026-06-02 | Chirfi Guindo | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 |
| 2026-06-02 | Christi Shaw | Independent Director | Other Derivative Acquisition | +19,676 | $29.55 |
| 2026-04-13 | Carole Ho | Former Independent Director | Intent to Sell (Form 144) | -87,784 | $30.73 |
| 2026-04-01 | Christine Bellon | Chief Legal Officer | Intent to Sell (Form 144) | -20,000 | $21.90 |
| 2026-04-01 | John Evans | Chief Executive Officer | Intent to Sell (Form 144) | -66,874 | $21.90 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.
Beam Therapeutics discussion 0 comments